Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats

[1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin

Marian Kruszynski, Bernard Lammek, Maurice Manning et al. · Journal of Medicinal Chemistry · 1980 · 448 citations

Neuropeptides, Altmetric Attention Score, Pharmacotherapy +20

Potential Role of Increased Sympathetic Activity in Impaired Sodium and Water Excretion in Cirrhosis

Daniel G. Bichet, Vicki J. Van Putten, Robert W. Schrier · New England Journal of Medicine · 1982 · 358 citations

Water Load, Hypertension, Electrolyte Disorder +19

Pathogenesis of Sodium and Water Retention in High-Output and Low-Output Cardiac Failure, Nephrotic Syndrome, Cirrhosis, and Pregnancy

Robert W. Schrier · New England Journal of Medicine · 1988 · 349 citations

Electrolyte Disorder, Heart Failure, Renal Function +10

Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V₂ receptor antagonist

Yoshitaka Yamamura, Hidenori Ogawa, Hiroshi Yamashita et al. · British Journal of Pharmacology · 1992 · 346 citations · Full text

Role of Vasopressin in Abnormal Water Excretion in Cirrhotic Patients

Daniel G. Bichet · Annals of Internal Medicine · 1982 · 312 citations